NETs clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
open to eligible people ages 24 months to 18 years
The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with somatostatin receptor (SSTR)-positive tumors.
at UCSF
Our lead scientists for NETs research studies include Kieuhoa Vo.
Last updated: